Anti-CD33 CAR-NK92 cells- PersonGen Biomedicine

Drug Profile

Anti-CD33 CAR-NK92 cells- PersonGen Biomedicine

Alternative Names: Anti-CD33 CAR-NK cells; Anti-CD33 CAR-NK92 cells; Anti-CD33 chimeric antigen receptor natural killer cell therapy - PersonGen Biomedicine; Anti-CD33 chimeric antigen receptor natural killer cells - PersonGen Biomedicine; Anti-CD33 chimeric antigen receptor natural killer92 cells - PersonGen Biomedicine; CAR-NK Cell immunotherapy - PersonGen Biomedicine

Latest Information Update: 07 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PersonGen Biomedicine
  • Class Cell therapies; Gene therapies
  • Mechanism of Action CD33 antigen inhibitors; Gene transference; Natural killer cell receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia

Most Recent Events

  • 01 Oct 2016 Phase-I/II clinical trials in Acute myeloid leukaemia (In adolescents, In adults, In children, In the elderly, Second-line therapy or greater) in China (Parenteral) (NCT02944162)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top